I-Mab Sponsored ADR (IMAB) Price Targets
| Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
|---|---|---|---|
| $7.25 | $10.00 | $5.00 | 321.51% |
Price Target
Based on short-term price targets offered by four analysts, the average price target for I-Mab Sponsored ADR comes to $7.25. The forecasts range from a low of $5.00 to a high of $10.00. The average price target represents an increase of 321.51% from the last closing price of $1.72.
Analyst Price Targets (4 )
Broker Rating
I-Mab Sponsored ADR currently has an average brokerage recommendation (ABR) of 1.25 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by four brokerage firms. The current ABR compares to an ABR of 1.25 a month ago based on four recommendations.
Of the four recommendations deriving the current ABR, three are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 75% and 25% of all recommendations. A month ago, Strong Buy made up 75%, while Buy represented 25%.
Broker Rating Breakdown
Brokerage Recommendations
| Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| ABR | 1.25 | 1.25 | 1.25 | 1.25 | 1.20 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
| Date | Brokerage Firm | Analyst | Previous | Current |
|---|---|---|---|---|
| 6/6/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
| 3/18/2024 | Piper Sandler | Joseph M Catanzaro | Strong Buy | Strong Buy |
| 3/18/2024 | H.C. Wainwright & Co. | Andrew S Fein | Strong Buy | Strong Buy |
| 3/15/2024 | Needham & Company | Gil J Blum | Moderate Buy | Moderate Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
| Current ABR | 1.25 |
| ABR (Last week) | 1.25 |
| # of Recs in ABR | 4 |
| Average Target Price | $7.25 |
| LT Growth Rate | NA |
| Industry | Medical - Biomedical and Genetics |
| Industry Rank by ABR | 75 of 252 |
| Current Quarter EPS Est: | -0.51 |